DiaSorin S.p.A. (VIE:DIAS)

Market Cap	3.33B -33.7%
Revenue (ttm)	1.20B +0.8%
Net Income	150.00M -20.3%
EPS	n/a
Shares Out	n/a
PE Ratio	22.17
Forward PE	15.61
Dividend	1.30 (2.13%)
Ex-Dividend Date	May 18, 2026

Volume	n/a
Average Volume	520
Open	60.78
Previous Close	61.60
Day's Range	60.58 - 60.84
52-Week Range	54.24 - 101.40
Beta	n/a
RSI	40.44
Earnings Date	Mar 20, 2026

About DiaSorin

DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, endocrinology, gastrointestinal infections, autoimmunity, hypertension, emergency/sepsis, bone metabolism, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urin...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1968
• Employees: 3,280
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: DIAS

Financial Performance

In 2025, DiaSorin's revenue was 1.20 billion, an increase of 0.81% compared to the previous year's 1.19 billion. Earnings were 150.00 million, a decrease of -20.26%.